SEC Form 4 · accession 0001144204-18-019057

Bionik Laboratories Corp. · BNKL

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Andre-Jacques Auberton-Herve

Director

Period of report

Mar 31, 2018

Accepted (ET)

Apr 3, 2018 · 7:26 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001508381

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1	Mar 31, 2018	C	12,114,710	$0.0625	A	12,679,436	I	Shares held through Star SCI
Common Stock^F2	Mar 31, 2018	C	564,726	$0.0625	A	12,679,436	I	Shares held through 4A Consulting and Engineering

Table II — derivative securities

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Warrant^F3	$0.0625	Aug 14, 2017	A	1,600,640	A	Mar 31, 2018	Aug 14, 2022	Common Stock	1,600,640	1,600,640	I

Explanation of responses

F1On March 31, 2018, an aggregate amount of $821,850 in convertible promissory notes converted in accordance with their terms into (i) 12,114,710 shares of the Issuer's common stock, and (ii) 1,040,152 shares of the Issuer's common stock (the "Pending Shares") that will be issued upon the earlier of (i) a reverse stock split of the Issuers's common stock that allows for the issuance of the Pending Shares without violating the authorized share number of the Issuer and (ii) an increase in the Issuer's authorized shares of common stock. The amounts set forth in this Form 4 do not reflect the issuance of the Pending Shares, and the Reporting Person will either amend this Form 4 or file a new Form 4 reflecting the issuance.
F2On March 31, 2018, an aggregate amount of $100,200 in convertible promissory notes converted in accordance with their terms into (i) 564,726 shares of the Issuer's common stock, and (ii) 1,039,115 shares of the Issuer's common stock (the "Pending Shares") that will be issued upon the earlier of (i) a reverse stock split of the Issuers's common stock that allows for the issuance of the Pending Shares without violating the authorized share number of the Issuer and (ii) an increase in the Issuer's authorized shares of common stock. The amounts set forth in this Form 4 do not reflect the issuance of the Pending Shares, and the Reporting Person will either amend this Form 4 or file a new Form 4 reflecting the issuance.
F3As of the transaction date, the number of shares of common stock underlying warrants and the exercise price were not yet determinable. Such number of shares and exercise price were each determined on March 31, 2018.